Focus on olanzapine

Current Medical Research and Opinion

Volumn 15, Issue 2, 1999, Pages 79-85

  Green, Ben ^a  

^a UNIVERSITY OF LIVERPOOL   (United Kingdom)

Author keywords

Antipsychotics; Neuroleptics; Olanzapine; Pharmacology; Schizophrenia

Indexed keywords

HALOPERIDOL; OLANZAPINE; RISPERIDONE; SERTINDOLE;

CLINICAL TRIAL; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG HALF LIFE; DRUG METABOLISM; DRUG STRUCTURE; ELECTROCARDIOGRAM; HUMAN; PSYCHOSIS; QT INTERVAL; REVIEW; SEXUAL DYSFUNCTION; SOMNOLENCE; WEIGHT GAIN;

EID: 0032980993     PISSN: 03007995     EISSN: None     Source Type: Journal    
DOI: 10.1185/03007999909113367     Document Type: Review

References (33)

1. Aizenberg, D., Zemishlany, Z., Dorfman-Etrog, P. et al. (1995). Sexual dysfunction in male schizophrenic patients. J. Clin. Psych., 56(4), 137-141.
2. Almond, S. and O'Donnell, O. (1998). Cost analysis of the treatment of schizophrenia in the UK. A comparison of olanzapine and haloperidol. Pharmacoeconomics. 13 (Suppl Pt 2), 575-588.
3. Beasley, C. M., Tollefson, G., Tran, P. et al. (1996). Olanzapine versus placebo and haloperidol: acute phase results of the North American double-blind olanzapine trial. Neuropsychopharmacol., 14(2), 111-123.
4. Bymaster, F. P., Calligaro, D. O., Falcone, J. F., et al. (1996). Radioreceptor binding profile of the atypical antipsychotic olanzapine. Neuropsychopharmacology, 14(2), 87-96.
5. Casey, D. E. (1996). Side effect profiles of new antipsychotic agents. J. Clin. Psych., 57 (Suppl 11), 40-45; discussion, 46-52.
6. Currier, G. W. and Simpson, G. M. (1998). Antipsychotic medications and fertility. Psych. Servs., 49(2), 175-176.
7. Debattista, C. Solvason, H. B., Belanoff, J. et al. (1997). Treatment of psychotic depression. Am. J. Psych., 154(11) [Letter], 1625-1626.
8. Ereshefsky, L. (1996). Pharmacokinetics and drug interactions: update for new antipsychotics. J. Clin. Psych., 57 (Suppl 11), 12-25.
9. Ganguli, R. and Brar, J. S. (1998). The effects of risperidone and olanzapine on the indications for clozapine. Psychopharmacol. Bull., 34(1), 83-87.
10. Glazer, W. M. and Johnstone, B. M. (1997). Pharmacoeconomic evaluation of antipsychotic therapy for schizophrenia. J. Clin. Psych., 58 (Suppl 10), 50-54.
11. Hamilton, S. H., Revicki, D. A., Genduso, L. A. et al. (1998). Olanzapine versus placebo and haloperidol: quality of life and efficacy results of the North American double-blind trial. Neuropsychopharmacol., 18(1), 41-49.
12. Ketter, T. A., Winsberg, M. E., DeGolia, S. G. et al. (1998). Rapid efficacy of olanzapine augmentation in nonpsychotic bipolar mixed states. J. Clin. Psych., 59(2): 83-85.
13. 3. Kumra, S., Jacobsen, L. K., Lenane, M. et al. (1998). Childhood-onset schizophrenia: an open-label study of olanzapine in adolescents. J. Am. Acad. Child. Adolesc. Psych., 37(4), 377-385.
14. Lieberman, J. A. (1996). Atypical antipsychotic drugs as a first-line treatment of schizophrenia: a rationale and hypothesis. J. Clin. Psych., 57 Suppl. 11, 68-71.
15. Littrell, K. H., Johnson, C. G., Littrell, S. et al. (1998). Marked reduction of tardive dyskinesia with olanzapine. Arch. Gen. Psych., 55(3), 279-280.
16. Martin, J., Gomez, J. C., Garcia-Bernardo, E. et al. (1997). Olanzapine in treatment-refractory schizophrenia: results of an open-label study. The Spanish Group for the Study of Olanzapine in Treatment-Refractory Schizophrenia. J. Clin. Psych., 58(11), 479-483.
17. Moore, N. A. (1995). Letter to the Editor. J. Psychopharmacol., 9, 155.
18. Nutt, D. J. (1994). Putting the 'A' in atypical: does alpha-2 adrenoceptor antagonism account for the therapeutic advantage of new antipsychotics? J. Psychopharmacol., 8, 193-195.
19. O'Brien, J. and Barber, R. (1998). Marked improvement in tardive dyskinesia following treatment with olanzapine in an elderly subject. Br. J. Psych., 172, 186.
20. Ravindran, A. V., Jones, B. W., al-Zaid, K. et al. (1997). Effective treatment of mania with olanzapine: 2 case reports. J. Psych. Neurosci., 22(5), 345-346.
21. Ring, B. J., Binkley, S. N., Vandenbranden, M. and Wrighton, S. A. (1996). In vitro interaction of the antipsychotic agent olanzapine with human cytochromes P450 CYP2C9, CYP2C19, CYP2D6 and CYP3A. Br. J. Clin. Pharmacol., 41(3), 181-186.
22. Sheitman, B. B., Lindgren, J. C. Early, J. and Sved, M. (1997). High-dose olanzapine for treatment-resistant schizophrenia. Am. J. Psych., 154 (11), 1626.
23. Stockton, M. E. and Rasmussen, K. (1990). Electrphysiological effects of olanzapine, a novel atypical antipsychotic, on A9 and A10 dopamin neurons. Neuropsychopharmacol., 14, 97-104.
24. Tollefson, G. D., Sanger, T. M. and Lieberman, J. A. (1997). Olanzapine versus haloperidol in the treatment of first episode psychosis. Schizo. Res., 24, Nos. 1 and 2.
25. Tollefson, G. D., Beasley, C. M., Tamura, R. N., Tran, P. V. and Potvin, J. H. (1997). Blind, controlled, long-term study of the comparative incidence of treatment-emergent tardive dyskinesia with olanzapine or haloperidol. Am. J. Psychiatry, 154(9), 1248-1254.
26. Tollefson, G. D. and Sanger, T. M. (1997). Negative symptoms: a path analytic approach to a double-blind, placebo- and haloperidol-controlled clinical trial with olanzapine. Am. J. Psych., 154(4), 466-474.
27. Tollefson, G. D., Beasley, C. M., Tran, P. V., Street, J. S., Krueger, J. A., Tamura, R. N., Graffeo, K. A. and Thieme, M. E. (1997). Olanzapine versus haloperidol in the treatment of schizophrenia and schizoaffective and schizophreniform disorders: results of an international collaborative trial. Am. J. Psych., 154(4), 457-465.
28. Tollefson, G. D., Sanger, T. M., Lu, Y. and Thieme, M. E. (1998). Depressive signs and symptoms in schizophrenia: a prospective blinded trial of olanzapine and haloperidol. Arch. Gen. Psych., 55(3), 250-258.
29. Tran, P. V., Dellva, M. A., Tollefson, G. D., Beasley, C. M., Potvin, J. H. and Kiesler, G. M. (1997). Extrapyramidal symptoms and tolerability of olanzapine versus haloperidol in the acute treatment of schizophrenia. J. Clin. Psych., 58(5), 205-211.
30. Tran, P. V., Hamilton, S. H., Kuntz, A. J., Potvin, J. H., Andersen, S. W., Beasley, C. and Tollefson, G. D. (1997). Double-blind comparison of olanzapine versus risperidone in the treatment of schizophrenia and other psychotic disorders. J. Clin. Psychopharmacol., 17(5), 407-418.
31. Tran, P. V., Dellva, M. A., Tollefson, G. D., Wentley, A. L. and Beasley, C. M. (1998). Oral olanzapine versus oral haloperidol in the maintenance treatment of schizophrenia and related psychoses. Br. J. Psych., 172, 499-505.
32. Weisler, R. H., Ahearn, E. P., Davidson, J. R. and Wallace, C. D. (1997). Adjunctive use of olanzapine in mood disorders: five case reports. Ann. Clin. Psych., 9(4), 259-262.
33. Zarate, C. A., Narendran, R., Tohen, M., Greaney, J. J., Berman, A., Pike, S. and Madrid, A. (1998). Clinical predictors of acute response with olanzapine in psychotic mood disorders. J. Clin. Psych., 59(1), 24-28.